Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

The user shared progress pictures showing significant hair regrowth after 6 months of using 1mg finasteride and 2.5mg minoxidil, with no side effects reported. They added Nizoral to their routine to address an itchy scalp.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

Dr. Tsuji's stem cell hair multiplication procedure may offer a future solution for hair loss, but it is initially expected to be very expensive, with prices potentially decreasing over time. In the meantime, users discuss using treatments like finasteride, despite side effects, to manage hair loss.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

User shared a 2-year progress update on hair regrowth using 1mg finasteride and 2.5mg oral minoxidil daily. They switched from topical to oral minoxidil for ease of use and showed significant improvement.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

A 27-year-old male experienced significant hair regrowth in two months using a daily oral 3-in-1 pill containing 1.1mg finasteride, 5mg minoxidil, and 1mg biotin from LockLab, with no side effects reported. The user also uses a derma-stamp twice a week to promote blood flow and stimulate growth.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

User shared 1-year progress using Finasteride, Minoxidil, and dermarolling with no side effects. Others discussed their experiences and asked questions about the treatments.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

A user shared their one-year progress using finasteride, minoxidil, derma roller, ketosol shampoo, omega 3, biotin, daily exercise, and a positive outlook. They also discussed their exercise routine and addressed a question about finasteride side effects.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

OP received their second bottle of a hair loss treatment and is asking who else is at the one-month mark. Users discuss their progress, with one user nearing two months of treatment.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

User noticed hair growth after 1.5 months using Fin, Min, stemoxydine, dermarolling, nizoral, and scalp massage. Others commented on promising results and potential improvement in 6 months.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.